Emily S. Gorell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emily S. Gorell has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Anne W. Lucky
Epidermolysis Bullosa Center, Division of Dermatology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
4 shared publications- Jean Yuh Tang
Department of Dermatology, Stanford University School of Medicine , Stanford, CA
4 shared publications - Alfred T. Lane
Department of Dermatology, Stanford School of Medicine, Stanford, CA, U.S.A.
3 shared publications Melissa Barriga
Department of Dermatology Stanford University School of Medicine Redwood City California USA
3 shared publicationsShufeng Li
Department of Dermatology Stanford University School of Medicine Redwood City California USA
3 shared publicationsAlbert S. Chiou
Department of Dermatology Stanford University School of Medicine Redwood City California USA
2 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 62-72
A Single Center Retrospective Chart Review of Monitoring Laboratory Tests in Recessive Dystrophic Epidermolysis Bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis characterized by skin fragility and systemic complications, including anemia, inflammation, and nutritional deficiencies. The prevalence and age of onset of monitoring laboratory tests remain poorly defined in the current literature. Objective: To characterize the frequency of nutritional deficiencies and earliest age of laboratory abnormalities in a cohort of RDEB patients. Methods: A retrospective chart review of 122 patients with RDEB seen at a tertiary care EB center (2010–2021) was conducted. Laboratory and anthropometric data from initial visits were stratified by age group and compared to institutional reference ranges. Results: Inflammatory markers were frequently elevated: C‐reactive protein (CRP) (100%, 74/74) and ESR (81%, 71/88), including in patients < 2 years. Anemia (86%, 98/114) and iron deficiency (84%, 80/95) were highly prevalent. Hypoalbuminemia was present in 69% of patients (77/112), particularly among those younger than 16 years. Thrombocytosis occurred in 41% (49/120). Anthropometric measures revealed early declines in weight‐for‐age and height‐for‐age percentiles and persistently low BMI. Mean height‐for‐age percentile decreased sharply from the 61st to the 30th %ile between ages 0–1.99 and 2–3.99 years. Vitamin D deficiency (using a 30 ng/mL cutoff) affected 49% (44/90), especially those > 8 years. Zinc and carnitine levels declined with increasing age, but the majority of patients had values within normal limits. Magnesium, selenium, phosphorus, and thyroid studies were within normal limits for most patients. Conclusions: Nutritional, hematologic, and inflammatory abnormalities are common and often present, even in infancy, among patients with RDEB. These findings underscore the need for standardized, age‐specific laboratory monitoring protocols beginning in early childhood. Early recognition of and intervention for abnormalities may improve long‐term outcomes in this medically complex population.
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 62-72
Open AccessA Single Center Retrospective Chart Review of Monitoring Laboratory Tests in Recessive Dystrophic Epidermolysis Bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis characterized by skin fragility and systemic complications, including anemia, inflammation, and nutritional deficiencies. The prevalence and age of onset of monitoring laboratory tests remain poorly defined in the current literature. Objective: To characterize the frequency of nutritional deficiencies and earliest age of laboratory abnormalities in a cohort of RDEB patients. Methods: A retrospective chart review of 122 patients with RDEB seen at a tertiary care EB center (2010–2021) was conducted. Laboratory and anthropometric data from initial visits were stratified by age group and compared to institutional reference ranges. Results: Inflammatory markers were frequently elevated: C‐reactive protein (CRP) (100%, 74/74) and ESR (81%, 71/88), including in patients < 2 years. Anemia (86%, 98/114) and iron deficiency (84%, 80/95) were highly prevalent. Hypoalbuminemia was present in 69% of patients (77/112), particularly among those younger than 16 years. Thrombocytosis occurred in 41% (49/120). Anthropometric measures revealed early declines in weight‐for‐age and height‐for‐age percentiles and persistently low BMI. Mean height‐for‐age percentile decreased sharply from the 61st to the 30th %ile between ages 0–1.99 and 2–3.99 years. Vitamin D deficiency (using a 30 ng/mL cutoff) affected 49% (44/90), especially those > 8 years. Zinc and carnitine levels declined with increasing age, but the majority of patients had values within normal limits. Magnesium, selenium, phosphorus, and thyroid studies were within normal limits for most patients. Conclusions: Nutritional, hematologic, and inflammatory abnormalities are common and often present, even in infancy, among patients with RDEB. These findings underscore the need for standardized, age‐specific laboratory monitoring protocols beginning in early childhood. Early recognition of and intervention for abnormalities may improve long‐term outcomes in this medically complex population.
- Open Access
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 93-99
Severe Junctional Epidermolysis Bullosa: Honoring Parental Values in Pediatric Palliative Decision‐Making
Severe junctional epidermolysis bullosa (JEB) is a rare, incurable, autosomal recessive blistering disorder with a uniformly poor prognosis. We present the case of a female infant diagnosed shortly after birth with genetically confirmed severe JEB, whose family prioritized comfort‐focused care and memory‐making over life‐prolonging interventions. Her interdisciplinary care centered on symptom relief, bonding, and alignment with family values. This case underscores the importance of early diagnosis and values‐based decision‐making in managing rare, life‐limiting conditions like severe JEB.
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 93-99
Open AccessSevere Junctional Epidermolysis Bullosa: Honoring Parental Values in Pediatric Palliative Decision‐Making
Severe junctional epidermolysis bullosa (JEB) is a rare, incurable, autosomal recessive blistering disorder with a uniformly poor prognosis. We present the case of a female infant diagnosed shortly after birth with genetically confirmed severe JEB, whose family prioritized comfort‐focused care and memory‐making over life‐prolonging interventions. Her interdisciplinary care centered on symptom relief, bonding, and alignment with family values. This case underscores the importance of early diagnosis and values‐based decision‐making in managing rare, life‐limiting conditions like severe JEB.
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 4
Guest Editor's Note on Epidermolysis Bullosa Special Issue
- 1 August 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (S2) , 4
Guest Editor's Note on Epidermolysis Bullosa Special Issue
- 31 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 84-87
Characterization of TNF ‐Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review
Tumor necrosis factor‐alpha inhibitors (TNFi) are used to treat various autoimmune diseases but can induce paradoxical psoriasiform dermatitis (PD) in a subset of patients. This retrospective chart review aimed to identify risk factors impacting PD severity in 70 pediatric patients at a single center. Forty patients (57.1%) discontinued their initial TNFi: 12/40 (30.0%) switched to another TNFi, with 4/12 (33.3%) experiencing PD recurrence, while 25/40 (62.5%) switched medication classes. Female sex was associated with increased use of high‐potency topical steroids ( p = 0.01), suggesting more severe disease. Juvenile idiopathic arthritis ( p = 0.02), older age ( p < 0.01), and concomitant immunomodulator use ( p = 0.04) were associated with a longer latency period before PD development.
- 31 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 84-87
Characterization of TNF ‐Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review
Tumor necrosis factor‐alpha inhibitors (TNFi) are used to treat various autoimmune diseases but can induce paradoxical psoriasiform dermatitis (PD) in a subset of patients. This retrospective chart review aimed to identify risk factors impacting PD severity in 70 pediatric patients at a single center. Forty patients (57.1%) discontinued their initial TNFi: 12/40 (30.0%) switched to another TNFi, with 4/12 (33.3%) experiencing PD recurrence, while 25/40 (62.5%) switched medication classes. Female sex was associated with increased use of high‐potency topical steroids ( p = 0.01), suggesting more severe disease. Juvenile idiopathic arthritis ( p = 0.02), older age ( p < 0.01), and concomitant immunomodulator use ( p = 0.04) were associated with a longer latency period before PD development.
- Open Access
- 16 April 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (4) , 279-291
Epidermolysis bullosa for primary care providers: A practical review
Epidermolysis bullosa (EB) is a group of genetic skin diseases, which manifest as fragile skin and blistering in addition to many extracutaneous conditions. Pediatricians and primary care providers play an integral role in managing these patients with multifaceted care needs. There are many resources to navigate treating the various manifestations of EB and to assist with the partnership between pediatricians, dermatologists, and other specialists. There are also newly approved therapies for treating some forms of EB. As patients may only attend the multidisciplinary clinic for the management of their condition at designated intervals, the primary care provider becomes the first point of contact in many acute or healthcare maintenance visits. Using the resources and tips discussed herein, the pediatrician can work with the rest of the medical team to best optimize the clinical outcomes of patients with EB.
- 16 April 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (4) , 279-291
Open AccessEpidermolysis bullosa for primary care providers: A practical review
Epidermolysis bullosa (EB) is a group of genetic skin diseases, which manifest as fragile skin and blistering in addition to many extracutaneous conditions. Pediatricians and primary care providers play an integral role in managing these patients with multifaceted care needs. There are many resources to navigate treating the various manifestations of EB and to assist with the partnership between pediatricians, dermatologists, and other specialists. There are also newly approved therapies for treating some forms of EB. As patients may only attend the multidisciplinary clinic for the management of their condition at designated intervals, the primary care provider becomes the first point of contact in many acute or healthcare maintenance visits. Using the resources and tips discussed herein, the pediatrician can work with the rest of the medical team to best optimize the clinical outcomes of patients with EB.
- 3 March 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (4) , 849-854
Junctional Epidermolysis Bullosa With Pyloric Atresia Complicated by Esophageal Atresia and Nephrotic Syndrome: A Case Report and Review of the Literature
Epidermolysis bullosa with associated pyloric atresia (EB‐PA) is a rare subtype of epidermolysis bullosa with a high mortality characterized by skin fragility, pyloric atresia, as well as renal and ureteral abnormalities. We present a unique case of EB‐PA in a newborn male further complicated by esophageal atresia and nephrotic syndrome. We review the previously reported nine cases of EB‐PA with esophageal atresia. However, to our knowledge, this case represents a previously unreported phenotype of EB‐PA with esophageal atresia and nephrotic syndrome.
- 3 March 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (4) , 849-854
Junctional Epidermolysis Bullosa With Pyloric Atresia Complicated by Esophageal Atresia and Nephrotic Syndrome: A Case Report and Review of the Literature
Epidermolysis bullosa with associated pyloric atresia (EB‐PA) is a rare subtype of epidermolysis bullosa with a high mortality characterized by skin fragility, pyloric atresia, as well as renal and ureteral abnormalities. We present a unique case of EB‐PA in a newborn male further complicated by esophageal atresia and nephrotic syndrome. We review the previously reported nine cases of EB‐PA with esophageal atresia. However, to our knowledge, this case represents a previously unreported phenotype of EB‐PA with esophageal atresia and nephrotic syndrome.
- 20 November 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (6) , 1121-1122
A call to action to address transition of care in pediatric dermatology
- 20 November 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (6) , 1121-1122
A call to action to address transition of care in pediatric dermatology
- Open Access
- 17 October 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-13
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating blistering genodermatosis caused by mutations in the COL7A1 gene, which encodes for type VII collagen and is necessary for dermal-epidermal adhesion and integrity. Disease manifestations include severe and debilitating wounds, aggressive squamous cell carcinomas, and premature death; however, there are currently no approved therapies. This Phase 1/2a, open-label study evaluated the long-term efficacy and safety of gene-corrected autologous keratinocyte grafts (EB-101) for chronic RDEB wounds. Methods: Autologous keratinocytes were harvested from participants with severe RDEB, transduced with a retrovirus containing the full-length COL7A1 gene, and grown into 5 × 7 cm (35 cm2) sheets. Gene-corrected keratinocyte sheets were then transplanted onto chronic RDEB wounds present for ≥ 12 weeks. Results: Seven adult participants with severe RDEB were grafted with six sheets each (42 total sheets) onto wounds and followed for a mean of 5.9 years (range 4–8 years). Long-term improvements in wound healing and symptoms were observed. At year five, 70% (21/30) of treated sites demonstrated ≥ 50% wound healing compared to baseline by investigator global assessment. No sites with ≥ 50% wound healing were painful or pruritic, compared to 67% (6/9) of sites with < 50% wound healing (p < 0.001) at year five. Grafts were well-tolerated throughout long-term follow-up. No serious adverse events related to treatment were reported over a mean of 5.9 years of follow-up. No persistent systemic autoimmunity against type VII collagen or replication-competent retrovirus infections were identified, and no participants developed squamous cell carcinomas related to treatment during long-term follow-up. Conclusions: Treatment with EB-101 appears safe and efficacious, and produces long-term improvements in wound healing, pain, and itch for RDEB patients. Results from the Phase 3 randomized controlled trial are forthcoming. Trial registration: ClinicalTrials.gov, NCT01263379. Registered December 15, 2010. https://clinicaltrials.gov/ct2/show/NCT01263379
- 17 October 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-13
Open AccessLong-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating blistering genodermatosis caused by mutations in the COL7A1 gene, which encodes for type VII collagen and is necessary for dermal-epidermal adhesion and integrity. Disease manifestations include severe and debilitating wounds, aggressive squamous cell carcinomas, and premature death; however, there are currently no approved therapies. This Phase 1/2a, open-label study evaluated the long-term efficacy and safety of gene-corrected autologous keratinocyte grafts (EB-101) for chronic RDEB wounds. Methods: Autologous keratinocytes were harvested from participants with severe RDEB, transduced with a retrovirus containing the full-length COL7A1 gene, and grown into 5 × 7 cm (35 cm2) sheets. Gene-corrected keratinocyte sheets were then transplanted onto chronic RDEB wounds present for ≥ 12 weeks. Results: Seven adult participants with severe RDEB were grafted with six sheets each (42 total sheets) onto wounds and followed for a mean of 5.9 years (range 4–8 years). Long-term improvements in wound healing and symptoms were observed. At year five, 70% (21/30) of treated sites demonstrated ≥ 50% wound healing compared to baseline by investigator global assessment. No sites with ≥ 50% wound healing were painful or pruritic, compared to 67% (6/9) of sites with < 50% wound healing (p < 0.001) at year five. Grafts were well-tolerated throughout long-term follow-up. No serious adverse events related to treatment were reported over a mean of 5.9 years of follow-up. No persistent systemic autoimmunity against type VII collagen or replication-competent retrovirus infections were identified, and no participants developed squamous cell carcinomas related to treatment during long-term follow-up. Conclusions: Treatment with EB-101 appears safe and efficacious, and produces long-term improvements in wound healing, pain, and itch for RDEB patients. Results from the Phase 3 randomized controlled trial are forthcoming. Trial registration: ClinicalTrials.gov, NCT01263379. Registered December 15, 2010. https://clinicaltrials.gov/ct2/show/NCT01263379
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1198-1201
Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey
Introduction: Dystrophic epidermolysis bullosa is a debilitating skin condition, without curative treatment. Previous research has focused on the recessive variant, which is known to cause severe disease. Limited work focusing on the clinical manifestations and outcomes of dominant dystrophic epidermolysis bullosa is found (DDEB).Methods: Analysis of an online survey of 42 DDEB patients.Results: Self‐reported severity of disease did not correlate with size of the wound or number of dressing changes, but did correlate with severity of pain reported in the last 12 months (3.4 mild vs 6.8 severe disease, P = 0.0002). Patients with severe DDEB also reported more severe internal disease symptoms, such as difficulty swallowing (62.5%, P = 0.01) and greater analgesic use during dressing changes (4.4% mild vs 81.3% severe, P = <0.001).Discussion: Patient perception of disease severity in DDEB appears to be most impacted by pain, presence of chronic open wounds, difficulty swallowing, difficulty walking, and anal strictures. As research on DDEB increases, future studies focused on these symptoms might be the most impactful for DDEB patients. However, distinguishing DDEB from other subtypes remains a challenge.
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1198-1201
Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey
Introduction: Dystrophic epidermolysis bullosa is a debilitating skin condition, without curative treatment. Previous research has focused on the recessive variant, which is known to cause severe disease. Limited work focusing on the clinical manifestations and outcomes of dominant dystrophic epidermolysis bullosa is found (DDEB).Methods: Analysis of an online survey of 42 DDEB patients.Results: Self‐reported severity of disease did not correlate with size of the wound or number of dressing changes, but did correlate with severity of pain reported in the last 12 months (3.4 mild vs 6.8 severe disease, P = 0.0002). Patients with severe DDEB also reported more severe internal disease symptoms, such as difficulty swallowing (62.5%, P = 0.01) and greater analgesic use during dressing changes (4.4% mild vs 81.3% severe, P = <0.001).Discussion: Patient perception of disease severity in DDEB appears to be most impacted by pain, presence of chronic open wounds, difficulty swallowing, difficulty walking, and anal strictures. As research on DDEB increases, future studies focused on these symptoms might be the most impactful for DDEB patients. However, distinguishing DDEB from other subtypes remains a challenge.